Magnesium deficiency in women after treatment of reproductive cancers. Clinical significance and solutions
Authors:   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Blinov D.V. ,   Institute of Preventive and Social Medicine, Moscow, Russian Federation,   F.P.Gaaz Moscow Medical and Social Institute, Moscow, Russian Federation, Solopova A.G. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Achkasov E.E. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Gromova O.A. ,   Federal Research Center “Informatics and Management”, Moscow, Russian Federation, Akavova S.A. ,   City Clinical Oncological Hospital No 1, Moscow, Russian Federation, Korabelnikov D.I. ,   F.P.Gaaz Moscow Medical and Social Institute, Moscow, Russian Federation, Bykovshchenko G.K. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation, Petrenko D.A. ,   I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
Published: February 2024

Objective. Clinical evaluation of magnesium deficiency (MD) in women in the recovery period after treatment of reproductive cancers. Patients and methods. Data from a multicenter observational study of MD in women with hormone-dependent disorders were analyzed. In a cohort of 9168 patients, women with a history of reproductive cancers (endometrial cancer, cervical cancer, ovarian cancer, vaginal cancer, breast cancer) were identified. Plasma magnesium concentrations were determined by a biochemical blood test. The clinical presentation of MD was evaluated using the Magnesium Deficiency Questionnaire (MDQ). Quality of life (QoL) was assessed using the World Health Organization Quality of Life-Brief Version (WHOQOL-BREF). In a part of women with MD, the dynamics of the studied parameters was evaluated after one month of magnesium supplementation. Results. A total of 70 (0.76%) patients in the recovery period after treatment of reproductive cancers were identified. High probability of MD according to MDQ was revealed in 57.1% of patients, intermediate risk – in 37.1%. Only 5.7% of women had no MD. Serum MD was present in 76.9% of patients. After one month of magnesium supplementation, 16.7% of patients had a high probability of MD according to MDQ, 66.7% had an intermediate risk of MD, and 16.7% had no MD. The number of patients with plasma MD was 33.3%. These women showed a significant reduction in the prevalence of symptoms such as cramps, nervousness, and muscle weakness. There was also a trend towards a reduction in irritability, and there was a significant improvement in the WHOQOL-BREF scores in terms of QoL (physical, psychological, and social domains). Conclusion. The obtained results emphasize the importance of magnesium level monitoring in women after treatment of reproductive cancers. Early detection and correction of MD is needed to prevent the development of MD-related symptoms, improve well-being and QoL. It is necessary to continue larger prospective studies of the clinical significance of MD in women undergoing rehabilitation after radical treatment of reproductive cancers. Key words: malignant neoplasms, cancer, reproductive system, magnesium deficiency, quality of life